<p>Maxim Group 分析師 Naz Rahman 重申了對 KZIA 股票的看漲態度，今天給予了買入評級。</p>
<h3>在 TipRanks 上享受 55% 的折扣</h3>
<ul>
<li>解鎖可信賴的數據驅動投資工具，使用 TipRanks Premium，從分析師評級和預測到最新消息和投資組合分析。</li>
<li>通過 TipRanks 智能投資者通訊發現高信心的股票推薦和新的投資機會。</li>
</ul>
<p>Naz Rahman 給予買入評級是基於與 paxalisib 相關的臨牀和市場背景的多種因素。他認為 Celcuity 在其 PI3K/mTOR 抑制劑的 III 期結果具有統計學顯著性，這增強了對整個類別的信心，並進一步驗證了 Kazia 採用的口服 PI3K/AKT/mTOR 藥物的有效性，該藥物在耐受性方面表現出令人鼓舞的結果，而沒有一些靜脈給藥方案中觀察到的高中性粒細胞減少率。</p>
<p>Rahman 還指出，Celcuity 即將到來的 PDUFA 決策以及 PI3K/mTOR 領域日益增長的交易活動表明該路徑中高質量資產的戰略價值正在上升。隨着 Kazia 擴大其三陰性乳腺癌試驗以及更廣泛的機制進一步降低風險，他降低了對 paxalisib 的收入風險假設，並將其 12 個月的目標價提高至 30 美元，進一步鞏固了對該股票的買入推薦。</p>
<p>在今天發佈的另一份報告中，H.C. Wainwright 也重申了對該股票的買入評級，目標價為 18.00 美元。</p>

KZIA

CELC

<p>Maxim Group 分析師 Naz Rahman 重申了對 Kazia Therapeutics (KZIA) 的買入評級，將 12 個月的目標價提高至 30 美元。此次評級上調反映了對 Kazia 的 PI3K/AKT/mTOR 戰略的信心增強，得益於 Celcuity 積極的三期臨牀試驗結果和降低風險的機制。此外，H.C. Wainwright 維持了買入評級，目標價為 18 美元</p>

<p>Maxim Group analyst Naz Rahman has reiterated their bullish stance on KZIA stock, giving a Buy rating today.</p>
<div class="lb-trans"><p>Maxim Group 分析師 Naz Rahman 重申了對 KZIA 股票的看漲態度，今天給予了買入評級。</p>
</div><h3>Claim 55% Off TipRanks</h3>
<div class="lb-trans"><h3>在 TipRanks 上享受 55% 的折扣</h3>
</div><ul>
<li>Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis.</li>
<li>Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter</li>
</ul>
<div class="lb-trans"><ul>
<li>解鎖可信賴的數據驅動投資工具，使用 TipRanks Premium，從分析師評級和預測到最新消息和投資組合分析。</li>
<li>通過 TipRanks 智能投資者通訊發現高信心的股票推薦和新的投資機會。</li>
</ul>
</div><p>Naz Rahman has given his Buy rating due to a combination of factors relating to both the clinical and market backdrop for paxalisib. He sees Celcuity’s statistically significant Phase 3 results with its PI3K/mTOR inhibitor as strengthening confidence in the entire class, and by extension validating Kazia’s approach with an orally administered PI3K/AKT/mTOR agent that has shown encouraging tolerability without the high neutropenia rates seen in some IV regimens.</p>
<div class="lb-trans"><p>Naz Rahman 給予買入評級是基於與 paxalisib 相關的臨牀和市場背景的多種因素。他認為 Celcuity 在其 PI3K/mTOR 抑制劑的 III 期結果具有統計學顯著性，這增強了對整個類別的信心，並進一步驗證了 Kazia 採用的口服 PI3K/AKT/mTOR 藥物的有效性，該藥物在耐受性方面表現出令人鼓舞的結果，而沒有一些靜脈給藥方案中觀察到的高中性粒細胞減少率。</p>
</div><p>Rahman also notes that Celcuity’s pending PDUFA decision and growing deal activity in the PI3K/mTOR arena suggest rising strategic value for high-quality assets in this pathway. With Kazia expanding its triple-negative breast cancer trial and the broader mechanism being further de-risked, he has reduced his revenue risk assumptions for paxalisib and raised his 12‑month price target to $30, reinforcing his Buy recommendation on the stock.</p>
<div class="lb-trans"><p>Rahman 還指出，Celcuity 即將到來的 PDUFA 決策以及 PI3K/mTOR 領域日益增長的交易活動表明該路徑中高質量資產的戰略價值正在上升。隨着 Kazia 擴大其三陰性乳腺癌試驗以及更廣泛的機制進一步降低風險，他降低了對 paxalisib 的收入風險假設，並將其 12 個月的目標價提高至 30 美元，進一步鞏固了對該股票的買入推薦。</p>
</div><p>In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $18.00 price target.</p>
<div class="lb-trans"><p>在今天發佈的另一份報告中，H.C. Wainwright 也重申了對該股票的買入評級，目標價為 18.00 美元。</p>
</div>

Analyst Raises Kazia’s Price Target to $30 and Reiterates Buy on Strengthened Confidence in PI3K/AKT/mTOR Strategy

分析師將 Kazia 的目標價上調至 30 美元，並基於對 PI3K/AKT/mTOR 策略增強的信心，重申買入評級